Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1983 Dec;42(3):890-9.
doi: 10.1128/iai.42.3.890-899.1983.

Monocyte-derived soluble suppressor factor(s) in patients with lepromatous leprosy

Comparative Study

Monocyte-derived soluble suppressor factor(s) in patients with lepromatous leprosy

M Sathish et al. Infect Immun. 1983 Dec.

Abstract

Peripheral blood monocytes from polar lepromatous leprosy (LL) patients were unable to support Mycobacterium leprae-induced in vitro lymphoproliferation of HLA-D-matched T cells from tuberculoid leprosy subjects, whereas those from responder individuals were able to do so. Monocyte-rich adherent cells from untreated LL patients released de novo soluble factors which inhibited antigen-induced lymphoproliferation to a greater extent and mitogenic responses to a lesser extent. Suppressive activity varied in different LL patients. However, the degree of suppression was similar in soluble factors obtained de novo and after treatment of adherent cells with heat-killed and freshly extracted, cryopreserved M. leprae. Treated patients showed less inhibition with de novo released soluble factors (27 +/- 7.7%) as compared to parallel soluble factors obtained after antigen treatment (44 +/- 4.8%) or with de novo soluble factors from untreated LL patients (62 +/- 14.2%). Similar supernatants from tuberculoid individuals showed no or insignificant effects on antigen-induced lymphoproliferation. The suppressive activity of LL soluble factors was produced for up to 72 h, was heat stable at 56 degrees C for 30 min, was indomethacin resistant, and resided in the greater than 25,000 molecular weight fraction.

PubMed Disclaimer

References

    1. Infect Immun. 1982 Apr;36(1):263-70 - PubMed
    1. Clin Exp Immunol. 1980 Sep;41(3):406-14 - PubMed
    1. N Engl J Med. 1982 Dec 23;307(26):1593-7 - PubMed
    1. Clin Exp Immunol. 1983 Mar;51(3):421-9 - PubMed
    1. Clin Exp Immunol. 1983 Mar;51(3):430-8 - PubMed

Publication types

Substances